API | vaniprevir

vaniprevir Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep. ^Wikipedia

Chemistry

SMILES: CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1
InChIKey: KUQWGLQLLVFLSM-ONAXAZCASA-N
Mol. Mass: 757.95
ALogP: 3.9 Partition coefficient
ChEMBL Molecules:

vaniprevir

vaniprevir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Hepatitis C virus genotype 1b (strain HC-J4) (HCV)) ^UniProt
- Genome polyprotein (Hepatitis C virus) ^UniProt
- Genome polyprotein (Hepatitis C virus) ^UniProt
- Non-structural protein 4A (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

mk7009 | mk 7009 | mk-7009 | vanihep | vaniprevir

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue